Kite Pharma, Inc.
KITE
KITE was delisted on the 2nd of October, 2017.
171 hedge funds and large institutions have $1.7B invested in Kite Pharma, Inc. in 2016 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 74 increasing their positions, 40 reducing their positions, and 40 closing their positions.
85% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 40
76% more call options, than puts
Call options by funds: $22.5M | Put options by funds: $12.7M
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
9% less funds holding
Funds holding: 187 → 171 (-16)
25% less capital invested
Capital invested by funds: $2.26B → $1.7B (-$557M)
35% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$25.6M |
| 2 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$18M |
| 3 |
State Street
Boston,
Massachusetts
|
+$15.1M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$9.35M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$9.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$40.3M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$12.4M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$11.8M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$8.91M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$8.08M |
KITE Hedge Fund Activity: Q1 2016 in Review
171 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Kite Pharma, Inc. (KITE) for Q1 2016, worth a combined $1.7B — down 25% from $2.26B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of KITE and 26 opened new positions — a net loss of 14 holders — while 40 trimmed existing stakes and 74 added.
The largest buyer was JP Morgan Chase, adding an estimated $25.6M. The largest seller was Fidelity Investments, cutting an estimated $40.3M.
- 171 institutional investors held Kite Pharma, Inc. (KITE) as of Q1 2016, down from 187 in Q4 2015.
- Funds reported $1.7B of Kite Pharma, Inc. stock for Q1 2016, down 25% quarter-over-quarter.
- 26 funds opened new Kite Pharma, Inc. positions in Q1 2016 and 40 closed out, a net change of -14 holders.
- The largest Kite Pharma, Inc. buyer in Q1 2016 was JP Morgan Chase, an estimated $25.6M added.
- The largest Kite Pharma, Inc. seller in Q1 2016 was Fidelity Investments, an estimated $40.3M sold.
Based on aggregated 13F filings for Q1 2016.